APOBEC-induced mutagenesis in cancer
TM Mertz, CD Collins, M Dennis… - Annual Review of …, 2022 - annualreviews.org
The initiation, progression, and relapse of cancers often result from mutations occurring
within somatic cells. Consequently, processes that elevate mutation rates accelerate …
within somatic cells. Consequently, processes that elevate mutation rates accelerate …
Genome instability in multiple myeloma
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal
proliferation of plasma cells and a heterogenous genomic landscape. Copy number and …
proliferation of plasma cells and a heterogenous genomic landscape. Copy number and …
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …
[HTML][HTML] Genomic landscape and chronological reconstruction of driver events in multiple myeloma
The multiple myeloma (MM) genome is heterogeneous and evolves through preclinical and
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
[HTML][HTML] Genomic patterns of progression in smoldering multiple myeloma
We analyzed whole genomes of unique paired samples from smoldering multiple myeloma
(SMM) patients progressing to multiple myeloma (MM). We report that the genomic …
(SMM) patients progressing to multiple myeloma (MM). We report that the genomic …
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma
MD Jain, B Ziccheddu, CA Coughlin… - Blood, The Journal …, 2022 - ashpublications.org
CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking
immunotherapies approved for use against large B-cell lymphomas. Although host …
immunotherapies approved for use against large B-cell lymphomas. Although host …
[HTML][HTML] Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
B Oben, G Froyen, KH Maclachlan… - Nature …, 2021 - nature.com
Multiple myeloma (MM) is consistently preceded by precursor conditions recognized
clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering …
clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering …
Revealing the impact of structural variants in multiple myeloma
EH Rustad, VD Yellapantula, D Glodzik… - Blood cancer …, 2020 - AACR
The landscape of structural variants (SV) in multiple myeloma remains poorly understood.
Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with …
Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with …
[HTML][HTML] Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
In multiple myeloma, next-generation sequencing (NGS) has expanded our knowledge of
genomic lesions, and highlighted a dynamic and heterogeneous composition of the tumor …
genomic lesions, and highlighted a dynamic and heterogeneous composition of the tumor …
[HTML][HTML] Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
A Keppler-Hafkemeyer, C Greil, PR Wratil… - Nature Cancer, 2023 - nature.com
Individuals with hematologic malignancies are at increased risk for severe coronavirus
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …